Introduction: CTNNB1 gene loss-of-function variants cause Neurodevelopmental disorder with spastic diplegia and visual defects (NEDSDV, OMIM 615075). Although motor impairment represents a core feature of this condition, the motor phenotype remains poorly described. We systematically assessed a cohort of 14 patients with disease-causing CTNNB1 variants to better characterize the movement disorder phenotype. Methods: patients were enrolled at Bambino Ges & ugrave; Children's Hospital in Rome, Italy, between January 2019 and February 2024. 14 participants were included and underwent extensive genetic and neurologic examination. Clinical features, neuroimaging and neurophysiological investigations were retrospectively analyzed from medical charts and video recordings. Results: 13 out of 14 patients showed motor disorders (one only showing mild coordination difficulties). 12 presented abnormal gait (11 patients with broad-based gait, one with narrow-based in-toeing gait, one with broad-based gait with unilateral intoeing). One did not achieve walking ability. 13 patients presented progressive lower limbs hypertonia without overt pyramidal signs. Five patients reported exaggerated startle, three developed upper body (prominently cervical) dystonia in the second decade, with or without bradykinesia (2/13). Treatment efficacy was variable: botulinum toxin was (at least partially) effective in 5/6, levodopa in 1 of 4 treated patients. Conclusions: CTNNB1-syndrome is associated with a peculiar, but recognizable movement disorder phenotype, encompassing complex gait disorders with progressive lower limb hypertonia, exaggerated startle, and possible occurrence in the second decade of life of upper body dystonia with or without bradykinesia.

Movement disorder phenotype in CTNNB1-syndrome: A complex but recognizable phenomenology / Garone, G.; Innocenti, A.; Grasso, M.; Mandarino, A.; Capuano, A.; Della Bella, G.; Frascarelli, F.; Diodato, D.; Onesimo, R.; Zampino, G.; Novelli, A.; Digilio, M. C.; Bartuli, A.; Dentici, M. L.; Parisi, P.; Galosi, S.; Tonduti, D.; Bertini, E.; Sinibaldi, L.; Specchio, N.. - In: PARKINSONISM & RELATED DISORDERS. - ISSN 1873-5126. - 126:(2024), pp. 1-5. [10.1016/j.parkreldis.2024.107057]

Movement disorder phenotype in CTNNB1-syndrome: A complex but recognizable phenomenology.

Garone G.;Dentici M. L.;Parisi P.;Galosi S.;Bertini E.;
2024

Abstract

Introduction: CTNNB1 gene loss-of-function variants cause Neurodevelopmental disorder with spastic diplegia and visual defects (NEDSDV, OMIM 615075). Although motor impairment represents a core feature of this condition, the motor phenotype remains poorly described. We systematically assessed a cohort of 14 patients with disease-causing CTNNB1 variants to better characterize the movement disorder phenotype. Methods: patients were enrolled at Bambino Ges & ugrave; Children's Hospital in Rome, Italy, between January 2019 and February 2024. 14 participants were included and underwent extensive genetic and neurologic examination. Clinical features, neuroimaging and neurophysiological investigations were retrospectively analyzed from medical charts and video recordings. Results: 13 out of 14 patients showed motor disorders (one only showing mild coordination difficulties). 12 presented abnormal gait (11 patients with broad-based gait, one with narrow-based in-toeing gait, one with broad-based gait with unilateral intoeing). One did not achieve walking ability. 13 patients presented progressive lower limbs hypertonia without overt pyramidal signs. Five patients reported exaggerated startle, three developed upper body (prominently cervical) dystonia in the second decade, with or without bradykinesia (2/13). Treatment efficacy was variable: botulinum toxin was (at least partially) effective in 5/6, levodopa in 1 of 4 treated patients. Conclusions: CTNNB1-syndrome is associated with a peculiar, but recognizable movement disorder phenotype, encompassing complex gait disorders with progressive lower limb hypertonia, exaggerated startle, and possible occurrence in the second decade of life of upper body dystonia with or without bradykinesia.
2024
Bradykinesia; CTNNB1; Dystonia; Movement disorders; Spastic diplegia
01 Pubblicazione su rivista::01a Articolo in rivista
Movement disorder phenotype in CTNNB1-syndrome: A complex but recognizable phenomenology / Garone, G.; Innocenti, A.; Grasso, M.; Mandarino, A.; Capuano, A.; Della Bella, G.; Frascarelli, F.; Diodato, D.; Onesimo, R.; Zampino, G.; Novelli, A.; Digilio, M. C.; Bartuli, A.; Dentici, M. L.; Parisi, P.; Galosi, S.; Tonduti, D.; Bertini, E.; Sinibaldi, L.; Specchio, N.. - In: PARKINSONISM & RELATED DISORDERS. - ISSN 1873-5126. - 126:(2024), pp. 1-5. [10.1016/j.parkreldis.2024.107057]
File allegati a questo prodotto
File Dimensione Formato  
Garone G et al_CTNNB1_2024.pdf

solo gestori archivio

Note: Garone_Movement disorder phenotype_2024
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 670.73 kB
Formato Adobe PDF
670.73 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1717316
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact